NextPharma Technologies Enters Partnership Agreement with Aseptic Technologies
Surrey, UK, 17th September, 2008
NextPharma, the leading European provider of product development, contract manufacturing and cold chain and logistics outsourcing services to the pharmaceutical and biotech industry, is pleased to announce that it has entered into a partnership agreement with Aseptic Technologies to manufacture sterile products using a new ‘closed vial’ technology.
Under this agreement NextPharma will sub-contract the filling of vials to Aseptic Technologies (at their site near to Brussels) for those NextPharma customers wishing to access this new technology – which involves the aseptic filling of vials, based on a completely closed system and using pre-sterilised plastic vials. NextPharma will continue to provide other services, including overall project management, directly to its customers.
Bill Wedlake, CEO, NextPharma Technologies, commented: ‘We are delighted to have reached this agreement with Aseptic Technologies which enables us to enhance further the service we provide for our customers enabling them to access this new technology through NextPharma.’
Patrick Balériaux, Managing Director, Aseptic Technologies, commented: “This collaboration with NextPharma is a real opportunity for Aseptic Technologies to offer direct access to the revolutionary Crystal® Closed Vial Technology to a broad base of pharmaceutical and biotech companies”.
NextPharma develops, manufactures, packages, and distributes a broad range of products and formulations for its customers from tablets and capsules to antibiotics, hormones and controlled release medicines. It has an established leadership position in the high technology area of injectables manufacturing, with particular expertise in product development and manufacture of oncology medicines.
Aseptic Technologies develops and manufactures innovative aseptic production equipment and devices for the pharmaceutical and biotech industries. Its core technology is designed to provide safer and easier sterility assurance for liquid aseptic filling operations.
Contact:
Bill Wedlake
Chief Executive Officer
NextPharma Technologies Holding Limited
Tel.: +44 (0) 1483 479 121
Notes to Editors:
About NextPharma
NextPharma Technologies, headquartered in the UK and founded in 2000, is world class provider of product development, contract manufacturing and distribution outsourcing services to the pharmaceutical, specialty pharmaceutical, generics and biotech industry.
It offers a broad range of services from early phase product development, through clinical trials supplies to high volume commercial manufacturing. NextPharma is a world leader in lyophilization, sterile fill-finish and pellet technologies and in specialist product manufacturing including cytotoxics, hormones, penicillins, cephalosporins and controlled substances. Its sterile development and production offers a full range of drug delivery technologies including pre-filled syringes, vials and ampoules.
NextPharma operates globally with seven product development centres, seven manufacturing plants and six storage and distribution sites across Europe and North America employing over 1,200 people. Across these locations NextPharma has built-up a strong track record in the development and manufacture of cytotoxics, hormones, antibiotics, pellets, sterile, solid, semi-solid, liquid and dry dosage forms, supplying customers in North America, Europe and Japan.
NextPharma has a customer base, which includes many of the world's leading pharmaceutical, specialty pharma and biotech companies.